Allspring Global Investments’s PTC Therapeutics PTCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.21M Sell
39,501
-8,370
-17% -$604K ﹤0.01% 982
2026
Q1
$3.29M Buy
47,871
+35,686
+293% +$2.53M 0.01% 948
2025
Q4
$935K Sell
12,185
-341
-3% -$24.8K ﹤0.01% 1178
2025
Q3
$777K Sell
12,526
-19
-0.2% -$990 ﹤0.01% 1224
2025
Q2
$613K Buy
12,545
+2,258
+22% +$107K ﹤0.01% 1284
2025
Q1
$524K Buy
+10,287
New +$513K ﹤0.01% 1439
2024
Q4
Sell
-47
Closed -$1.74K 2255
2024
Q3
$1.74K Sell
47
-960
-95% -$32.1K ﹤0.01% 2276
2024
Q2
$30.8K Sell
1,007
-567
-36% -$18.4K ﹤0.01% 2035
2024
Q1
$45.8K Buy
+1,574
New +$44.1K ﹤0.01% 1962
2023
Q4
Sell
-5,075
Closed -$114K 2632
2023
Q3
$114K Buy
5,075
+559
+12% +$20.8K ﹤0.01% 1948
2023
Q2
$184K Buy
4,516
+63
+1% +$3.08K ﹤0.01% 1837
2023
Q1
$216K Sell
4,453
-141
-3% -$6.45K ﹤0.01% 1795
2022
Q4
$175K Buy
4,594
+26
+0.6% +$1.08K ﹤0.01% 1867
2022
Q3
$229K Hold
4,568
﹤0.01% 1781
2022
Q2
$182K Sell
4,568
-27,079
-86% -$950K ﹤0.01% 1842
2022
Q1
$1.18M Buy
31,647
+1,428
+5% +$55K ﹤0.01% 1785
2021
Q4
$1.2M Buy
+30,219
New +$1.16M ﹤0.01% 1825

Other funds holding PTCT

Allspring Global Investments's PTCT Position: Q2 2026 in Review

Allspring Global Investments reduced its PTC Therapeutics (PTCT) stake by 17% in Q2 2026, selling an estimated $604K and leaving 39,501 shares worth $3.21M. The position accounts for ﹤0.01% of the portfolio, ranked #982.

Allspring Global Investments first reported a position in PTCT in Q4 2021 and has held it in 17 quarters since. The position peaked at $3.29M in Q1 2026. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Allspring Global Investments held 39,501 shares of PTC Therapeutics worth $3.21M as of Q2 2026.
  • Allspring Global Investments sold 8,370 PTC Therapeutics shares in Q2 2026, an estimated $604K.
  • PTC Therapeutics made up ﹤0.01% of Allspring Global Investments's portfolio in Q2 2026, its #982 holding.
  • Allspring Global Investments first reported a position in PTC Therapeutics in Q4 2021 and has held it in 17 quarters since.
  • Allspring Global Investments's PTC Therapeutics position peaked at $3.29M in Q1 2026.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Allspring Global Investments's 13F filing for Q2 2026, filed 13 Aug 2026.